Dimitris Mavroudis

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients

Galatea Kallergi, Maria A. Papadaki, Eleni Politaki et al. · Breast Cancer Research · 2011 · 372 citations · Full text

Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer

Panayiotis A. Theodoropoulos, Hara Polioudaki, Sofia Agelaki et al. · Cancer Letters · 2009 · 285 citations

Breast Oncology, Medicine, Stem Cell Mobilization +11

Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer Patients

N. Xenidis, Maria Perraki, Maria Kafousi et al. · Journal of Clinical Oncology · 2006 · 265 citations · Full text

Different Prognostic Value of Cytokeratin-19 mRNA–Positive Circulating Tumor Cells According to Estrogen Receptor and HER2 Status in Early-Stage Breast Cancer

Michail Ignatiadis, N. Xenidis, Maria Perraki et al. · Journal of Clinical Oncology · 2007 · 240 citations · Full text